首页> 美国卫生研究院文献>Nucleic Acids Research >Elimination of unaltered DNA in mixed clinical samples via nuclease-assisted minor-allele enrichment
【2h】

Elimination of unaltered DNA in mixed clinical samples via nuclease-assisted minor-allele enrichment

机译:通过核酸酶辅助微量等位基因富集消除混合临床样品中未改变的DNA

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Presence of excess unaltered, wild-type (WT) DNA providing no information of biological or clinical value often masks rare alterations containing diagnostic or therapeutic clues in cancer, prenatal diagnosis, infectious diseases or organ transplantation. With the surge of high-throughput technologies there is a growing demand for removing unaltered DNA over large pools-of-sequences. Here we present nuclease-assisted minor-allele enrichment with probe-overlap (NaME-PrO), a single-step approach with broad genome coverage that can remove WT-DNA from numerous sequences simultaneously, prior to genomic analysis. NaME-PrO employs a double-strand-DNA-specific nuclease and overlapping oligonucleotide-probes interrogating WT-DNA targets and guiding nuclease digestion to these sites. Mutation-containing DNA creates probe-DNA mismatches that inhibit digestion, thus subsequent DNA-amplification magnifies DNA-alterations at all selected targets. We demonstrate several-hundred-fold mutation enrichment in diverse human samples on multiple clinically relevant targets including tumor samples and circulating DNA in 50-plex reactions. Enrichment enables routine mutation detection at 0.01% abundance while by adjusting conditions it is possible to sequence mutations down to 0.00003% abundance, or to scan tumor-suppressor genes for rare mutations. NaME-PrO introduces a simple and highly parallel process to remove un-informative DNA sequences and unmask clinically and biologically useful alterations.
机译:没有提供生物学或临床价值信息的过量未改变的野生型(WT)DNA的存在通常掩盖了罕见的改变,其中包含癌症,产前诊断,传染病或器官移植的诊断或治疗线索。随着高通量技术的兴起,人们越来越需要在大序列池中去除未改变的DNA。在这里,我们介绍了带有探针重叠(NaME-PrO)的核酸酶辅助小等位基因富集,这是一种具有广泛基因组覆盖范围的单步方法,可以在基因组分析之前同时从众多序列中去除WT-DNA。 NaME-PrO采用双链DNA特异性核酸酶和重叠的寡核苷酸探针来询问WT-DNA靶标,并指导核酸酶消化至这些位点。含有突变的DNA会产生探针-DNA错配,从而抑制消化,因此随后的DNA扩增会放大所有选定靶点的DNA改变。我们证明了多种临床相关目标(包括肿瘤样本和50多重反应中的循环DNA)在多种人类样本中的数百倍突变富集。富集使得能够以0.01%的丰度进行常规突变检测,而通过调节条件,可以将突变的序列降低至0.00003%的丰度,或扫描肿瘤抑制基因的罕见突变。 NaME-PrO引入了一个简单且高度并行的过程,以去除非信息性的DNA序列并揭露临床和生物学上有用的改变。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号